American Journal of Kidney Diseases
Volume 53, Issue 4, Supplement 4 , Pages S22-S31 , April 2009

Hypertension in Early-Stage Kidney Disease: An Update From the Kidney Early Evaluation Program (KEEP)

  • Rigas Kalaitzidis, MD

      Affiliations

    • Department of Medicine, Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Pritzker School of Medicine, Chicago, IL
    • ,
  • Suying Li, PhD

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • ,
  • Changchun Wang, MS

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • ,
  • Shu-Cheng Chen, MS

      Affiliations

    • Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN
    • ,
  • Peter A. McCullough, MD, MPH

      Affiliations

    • Department of Medicine, Divisions of Cardiology, Nutrition, and Preventive Medicine, William Beaumont Hospital, Royal Oak, MI
    • ,
  • George L. Bakris, MD

      Affiliations

    • Department of Medicine, Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Pritzker School of Medicine, Chicago, IL
    • Corresponding Author InformationAddress correspondence to George L. Bakris, MD, University of Chicago School of Medicine, 5841 South Maryland Ave, MC 1027, Chicago, IL 60637

Received 29 October 2008 ,Accepted 26 November 2008.

References 

  1. Tu K, Chen Z, Lipscombe LL. Prevalence and incidence of hypertension from 1995 to 2005: A population-based study. CMAJ. 2008;178:1429–1435
  2. Ong KL, Cheung BM. Response to nonpharmacological treatment of hypertension: Impact on prevalence estimates. Hypertension. 2007;50:e2
  3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199–206
  4. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension. 2004;44:398–404
  5. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146
  6. Balu S, Thomas J. Incremental expenditure of treating hypertension in the United States. Am J Hypertens. 2006;19:810–816
  7. Schoolwerth AC, Engelgau MM, Hostetter TH, et al. Chronic kidney disease: A public health problem that needs a public health action plan. Prev Chronic Dis. 2006;3:A57;(abstr)
  8. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  9. So WY, Kong AP, Ma RC, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care. 2006;29:2046–2052
  10. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008;51(suppl 2):S30–S37
  11. McCullough PA, Li S, Jurkovitz CT, et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(suppl 2):S38–S45
  12. McFarlane SI, Chen SC, Whaley-Connell AT, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(suppl 2):S46–S55
  13. Vassalotti JA, Uribarri J, Chen SC, et al. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(suppl 2):S56–S68
  14. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(suppl 2):B54–B64
  15. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952–1961
  16. Schaeffner ES, Kurth T, Bowman TS, Gelber RP, Gaziano JM. Blood pressure measures and risk of chronic kidney disease in men. Nephrol Dial Transplant. 2008;23:1246–1251
  17. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL Study. Arch Intern Med. 2003;163:1555–1565
  18. Jurkovitz CT, Qiu Y, Wang C, Gilbertson DT, Brown WW. The Kidney Early Evaluation Program (KEEP): Program design and demographic characteristics of the population. Am J Kidney Dis. 2008;51(suppl 2):S3–S12
  19. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  20. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254
  21. Stevens LA, Stoycheff N. Standardization of serum creatinine and estimated GFR in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008;51(suppl 2):S77–S82
  22. La Vange LM, Stearns SC, Lafata JE, Koch GG, Shah BV. Innovative strategies using SUDAAN for analysis of health surveys with complex samples. Stat Methods Med Res. 1996;5:311–329
  23. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. Metabolic syndrome and incident end-stage peripheral vascular disease: A 14-year follow-up study in elderly Finns. Diabetes Care. 2007;30:3099–3104
  24. Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005;46:1309–1315
  25. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004;65:2309–2320
  26. Ibsen H, Wachtell K, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Kidney Int Suppl. 2004;66:S56–S58
  27. Xue JL, Eggers PW, Agodoa LY, Foley RN, Collins AJ. Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged Medicare beneficiaries. J Am Soc Nephrol. 2007;18:1299–1306
  28. Duru OK, Li S, Jurkovitz C, et al. Race and sex differences in hypertension control in CKD: Results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008;51:192–198
  29. Collins AJ, Li S, Chen SC, Vassalotti JA. Participant follow-up in the Kidney Early Evaluation Program (KEEP) after initial detection. Am J Kidney Dis. 2008;51(suppl 2):S69–S76
  30. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549–1555
  31. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D. Obesity and prevalent and incident CKD: The Hypertension Detection and Follow-Up Program. Am J Kidney Dis. 2005;46:587–594
  32. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870–1876
  33. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–28
  34. Bakris GL, Sowers JR ASH Position paper. Treatment of hypertension in patients with diabetes—An update. J Clin Hypertens (Greenwich). 2008;10:707–713

PII: S0272-6386(09)00024-9

doi: 10.1053/j.ajkd.2008.11.028

American Journal of Kidney Diseases
Volume 53, Issue 4, Supplement 4 , Pages S22-S31 , April 2009

Article Tools

* Image Usage & Resolution